摘要
目的:分析人表皮生长因子受体2(Human epidermal growth factor receptor-2,HER-2)阳性乳腺癌患者经补血养心抗癌汤辅助多西他赛+卡铂化疗方案治疗前后血清前蛋白转化酶枯草溶菌素9(Recombinant Proprotein Convertase Subtilisin/Kexin Type,PCSK9)、趋化因子配体20(,CCL20)水平的变化。方法:回顾性分析2021年1月—2023年1月82例HER-2阳性乳腺癌患者资料,按不同治疗方案分为对照组、观察组,各41例。对照组采用多西他赛+卡铂化疗方案治疗,观察组采用补血养心抗癌汤辅助多西他赛+卡铂化疗方案治疗,21 d为1个周期,2组均持续治疗6个周期。比较2组临床疗效、中医证候积分、HER-2表达、PCSK9、CCL20及不良反应。结果:观察组临床有效率(58.54%)高于对照组(36.59%);与对照组比较,治疗后观察组中医证候主症、次症、总积分均较低;治疗后观察组HER-2转阴率高于对照组,HER-2强阳表达率低于对照组;与治疗前比较,2组PCSK9、CCL20均降低,且观察组更为显著,差异均有统计学意义。2组恶心呕吐、脱发、心脏毒性、骨髓抑制等不良反应发生率比较,无明显差异。结论:补血养心抗癌汤辅助多西他赛+卡铂化疗方案治疗HER-2阳性乳腺癌可下调PCSK9、CCL20表达,有效控制病情、促进HER-2转阴,疗效显著,且安全性高。
Objective:To analyze the changes in serum proprotein convertase subtilisin/kexin type 9(PCSK9)and chemokine ligand 20(CCL20)levels in patients with human epidermal growth factor receptor-2(HER-2)positive breast cancer before and after treatment with Buxue Yangxin Kangai Decoction assisted with docetaxel+carboplatin chemotherapy.Methods:The data of 82 patients with HER-2 positive breast cancer from January 2021 to January 2023 were retrospectively analyzed and divided into a control group and an observation group according to different treatment regimens,with 41 cases in each group.The control group was treated with docetaxel+carboplatin chemotherapy,and the observation group was treated with Buxue Yangxin Kangai Decoction assisted with docetaxel+carboplatin chemotherapy.One cycle was 21 days,and both groups were treated for 6 cycles.The clinical efficacy,TCM syndrome score,HER-2 expression,PCSK9,CCL20 and adverse reactions were compared between the two groups.Results:The clinical efficacy of the observation group(58.54%)was higher than that of the control group(36.59%);compared with the control group,the main symptoms,secondary symptoms and total score of TCM syndrome in the observation group after treatment were lower;after treatment,the HER-2 negative conversion rate in the observation group was higher than that in the control group,and the HER-2 strong positive expression rate was lower than that in the control group;compared with before treatment,PCSK9 and CCL20 in both groups decreased,and the observation group was more significant,and the differences were statistically significant.There was no significant difference in the incidence of adverse reactions such as nausea and vomiting,alopecia,cardiotoxicity,and bone marrow suppression between the two groups.Conclusion:The Buxue Yangxin Kangai Decoction assisted with docetaxel+carboplatin chemotherapy regimen can downregulate the expression of PCSK9 and CCL20 in the treatment of HER-2 positive breast cancer,effectively control the disease,promote HER-2 negative conversion,and has significant efficacy and high safety.
作者
贾佳
孟林凡
于东波
JIA Jia;MENG Linfan;YU Dongbo(Xuchang Traditional Chinese Medicine Hospital,Henan Xuchang 461000,China)
出处
《中医药临床杂志》
2024年第9期1772-1776,共5页
Clinical Journal of Traditional Chinese Medicine
